DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/lcqtbd/china_contract) has announced the addition of the "China Contract Research Organization (CRO) Industry Report, 2012-2013" report to their offering.
Compared to Europe and America, China developed pharmaceutical CRO industry 40 years later, with domestic industrial players amounting to over 500, most of which are SMEs. In general, Chinese CRO market scale occupies only 7%-10% of the world's total, and in 2011-2012 the CRO market size of China approximated RMB22-28 billion.
Considering huge potentials of Chinese pharmaceutical market, intensive talent resource, relatively low cost and rich spectrum of diseases, foreign enterprises are accelerating to expand CRO market there. Presently, world-renowned CRO companies including Quintiles, Covance, PPD, CRL and ICON have set foot in China by building new establishments and M&As. In China, homegrown leaders cover WuXi AppTec Co., Ltd., Shanghai-headquartered ShangPharma Corporation, and Hangzhou Tigermed Consulting, with the respective revenue in Jan.-Sep., 2012 hitting USD374 million, USD94.47 million and USD29.84 million, the combined proportion of 14% in China CRO market.
In an aim to realize resource sharing and improve overall competitiveness, some domestic pharmaceutical CRO enterprises seek joint development by setting up alliance.
Key Topics Covered
1. Overview of CRO Industry
1.1 Definition & Classification
1.2 Industry Background
2. Development Environment of CRO Industry in China
2.1 International Environment
2.2 Industry Environment
2.3 Policy Environment
3. Market Analysis of CRO Industry in China
3.1 Status Quo
3.2 Market Size
3.3 Competition Pattern
3.4 Regional Market
4.Key CRO Enterprises Worldwide
5.Key CRO Enterprises in China
- Charles River Laboratories International
- PAREXEL International
- Quintiles Transnational Corp.
- ShangPharma Corporation
- Sundia MediTech Co.
- Tigermed Consulting Co.
- Venturepharm Laboratories
- WuXi AppTec Co.
For more information visit http://www.researchandmarkets.com/research/lcqtbd/china_contract